We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » COVID-19

COVID-19
%{topic} RSS Feed RSS

EMA Issues New Guidance for Variant-Modified COVID-19 Vaccines

February 26, 2021
The European Medicines Agency (EMA) has issued new guidance outlining requirements for drug manufacturers that modify their COVID-19 vaccines to protect against several emerging variants to SARS-CoV-2. Read More

FDA Approves Pfizer’s Request to Raise Vaccine Storage Temperature

February 26, 2021
The FDA has approved Pfizer’s and BioNtech’s request for a revised Emergency Use Authorization (EUA) permitting their COVID-19 vaccine to be stored at normal pharmaceutical freezer temperatures. Read More

AstraZeneca Still Aiming to Deliver on Second Quarter Commitment to EU

February 26, 2021
Despite facing significant delays in supplying the European Union with its ordered AstraZeneca (AZ)/Oxford COVID-19 vaccine doses, AZ has said that it is using a large number of doses made via its international supply chain to meet its second-quarter supply commitments with Europe. Read More

Israel Finds Pfizer/BioNTech Vaccine Effective Across All Age Groups

February 26, 2021
The Pfizer/BioNTech COVID-19 vaccine showed the same effectiveness for all age groups — including individuals over age 60 — confirmed a new study from Israel that included almost 1.2 million individuals. Read More

Experimental GSK Treatment May Help Elderly, Hospitalized COVID-19 Patients

February 26, 2021
Significantly more hospitalized COVID-19 patients aged 70 and up were alive and free of respiratory failure after treatment with GlaxoSmithKline’s (GSK) investigational monoclonal antibody otilimab in a phase 2 clinical trial, the company said Thursday. Read More

Pfizer and BioNTech Kick Off Study Evaluating Booster Shot Against South African Variant

February 26, 2021
Pfizer and BioNTech have begun assessing the safety and immunogenicity of a third dose of their COVID-19 vaccine against the coronavirus’ South African mutation and other potential viral variants. Read More

Ghana Gets 600,000 COVID-19 Vaccines From COVAX

February 25, 2021
Ghana is the first country outside of India to get the COVID-19 vaccine from COVAX, the World Health Organization’s (WHO) eight-month-old vaccine-sharing program. Read More

China’s Sinopharm and CanSino Biologics Apply for Public Use Authorization of Their COVID-19 Vaccines

February 25, 2021
Sinopharm, a unit of China National Pharmaceutical Group, and Chinese company CanSino Biologics have applied for public use of their COVID-19 vaccines in China. If approved, China would have four approved vaccines that were developed domestically. Read More

Biden Signs Executive Order to Review U.S. Supply Chain

February 25, 2021
President Biden signed an executive order Wednesday mandating a review of the U.S. supply chain for critical goods, including materials needed for manufacturing COVID-19 products — fulfilling a promise he made on the campaign trail. Read More

FDA’s Review of Johnson & Johnson Vaccine Finds It Safe and Effective for Emergency Authorization

February 25, 2021
The FDA has published a briefing document ahead of Friday’s advisory panel meeting showing that agency staff have found the promising, single-shot Johnson & Johnson COVID-19 vaccine safe and effective enough for Emergency Use Authorization (EUA). Read More

NIH to Begin Evaluating Moderna Vaccine Modified Against South African Strain

February 25, 2021
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) will soon begin a phase 1 clinical trial of Moderna’s variant-specific COVID-19 vaccine candidate, mRNA-1273.351, which has been tailored to better protect against the virus’ South African mutation. Moderna will also conduct trials of its own. Read More

WHO Compensation Program for COVID-19 Vaccine Side Effects Launched

February 24, 2021
The World Health Organization (WHO) this week announced a vaccine injury compensation plan for the 92 low- and middle-income countries that are getting COVID-19 vaccines through its COVAX initiative. Read More
Previous 1 2 3 4 5 6 7 8 9 … 121 122 Next

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing